Search Results

There are 11966 results for: content related to: A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer

  1. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting and Susanne Unverzagt

    Published Online : 11 JUL 2012, DOI: 10.1002/14651858.CD008941.pub2

  2. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Article first published online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  3. Anti-angiogenic therapies for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting and Susanne Unverzagt

    Published Online : 8 JUL 2009, DOI: 10.1002/14651858.CD005392.pub3

  4. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 7, July 2014, Pages: 726–734, Axel Grothey, E. Dawn Flick, Allen L. Cohn, Tanios S. Bekaii-Saab, Johanna C. Bendell, Mark Kozloff, Nancy Roach, Yong Mun, Susan Fish and Herbert I. Hurwitz

    Article first published online : 16 MAY 2014, DOI: 10.1002/pds.3633

  5. Angiogenesis inhibitors for the treatment of ovarian cancer

    Intervention Review

    The Cochrane Library

    Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum and Jo Morrison

    Published Online : 7 SEP 2011, DOI: 10.1002/14651858.CD007930.pub2

  6. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

    Head & Neck

    Matthew G. Fury, Han Xiao, Eric J. Sherman, Shrujal Baxi, Stephanie Smith–Marrone, Karen Schupak, Richard Gewanter, Daphna Gelblum, Sofia Haque, Heiko Schoder, Jatin P. Shah, Nora Katabi, Rachel Kurtzman, Brynna Lipson, Lisa Cox, Nancy Y. Lee and David G. Pfister

    Article first published online : 6 JUL 2015, DOI: 10.1002/hed.24041

  7. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

    British Journal of Surgery

    Volume 98, Issue 3, March 2011, Pages: 399–407, D. A. Wicherts, R. J. de Haas, M. Sebagh, E. Saenz Corrales, D. L. Gorden, F. Lévi, B. Paule, D. Azoulay, D. Castaing and R. Adam

    Article first published online : 15 DEC 2010, DOI: 10.1002/bjs.7368

  8. Retina, Vitreous

    Clinical & Experimental Ophthalmology

    Volume 36, Issue s1, June 2008, Pages: A459–A584,

    Article first published online : 18 JUL 2008, DOI: 10.1111/j.1442-9071.2008.01760.x

  9. You have free access to this content
    Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

    Intervention Review

    The Cochrane Library

    Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik and Barbara S Hawkins

    Published Online : 29 AUG 2014, DOI: 10.1002/14651858.CD005139.pub3

  10. Bevacizumab (Avastin)

    Handbook of Therapeutic Antibodies

    Eduardo Díaz-Rubio, Edith A. Perez, Guiseppe Giaccone, Pages: 779–812, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch29

  11. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

    Intervention Review

    The Cochrane Library

    Lorenzo Moja, Ersilia Lucenteforte, Koren H Kwag, Vittorio Bertele, Annalisa Campomori, Usha Chakravarthy, Roberto D'Amico, Kay Dickersin, Laurent Kodjikian, Kristina Lindsley, Yoon Loke, Maureen Maguire, Daniel F Martin, Alessandro Mugelli, Bernd Mühlbauer, Isabel Püntmann, Barnaby Reeves, Chris Rogers, Christine Schmucker, Manju L Subramanian and Gianni Virgili

    Published Online : 15 SEP 2014, DOI: 10.1002/14651858.CD011230.pub2

  12. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

    Journal of Evaluation in Clinical Practice

    Volume 18, Issue 2, April 2012, Pages: 247–255, Jignesh J. Patel, Margaret A.S. Mendes, Mark Bounthavong, Melissa L.D. Christopher, Daniel Boggie and Anthony P. Morreale

    Article first published online : 16 SEP 2010, DOI: 10.1111/j.1365-2753.2010.01546.x

  13. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

    Head & Neck

    Min Yao, Nicholas Galanopoulos, Pierre Lavertu, Pingfu Fu, Michael Gibson, Athanassios Argiris, Rod Rezaee, Chad Zender, Jay Wasman, Mitchell Machtay and Panos Savvides

    Article first published online : 29 OCT 2014, DOI: 10.1002/hed.23813

  14. You have free access to this content
    Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

    Acta Ophthalmologica

    Volume 91, Issue 4, June 2013, Pages: e304–e310, Yu Xu, Qi Zhang, Xiaoli Kang, Ying Zhu, Jiakai Li, Yiye Chen and Peiquan Zhao

    Article first published online : 7 MAY 2013, DOI: 10.1111/aos.12055

  15. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery

    Acta Ophthalmologica

    Tine Van Bergen, Evelien Vandewalle, Lieve Moons and Ingeborg Stalmans

    Article first published online : 18 MAY 2015, DOI: 10.1111/aos.12766

  16. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

    Cancer

    Volume 121, Issue 9, May 1, 2015, Pages: 1456–1462, Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

    Article first published online : 29 DEC 2014, DOI: 10.1002/cncr.29234

  17. You have free access to this content
    A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment

    International Journal of Cancer

    Volume 131, Issue 4, 15 August 2012, Pages: 956–969, Hongzheng Zhang, Sujin Yun, Thil D. Batuwangala, Michael Steward, Steve D. Holmes, Lin Pan, Mourad Tighiouart, Hyung Ju C. Shin, Lydia Koenig, Wungki Park, Daniel Rycroft, Sreenivas Nannapaneni, Yuxiang Wang, Zhuo (Georgia) Chen and Dong M. Shin

    Article first published online : 19 NOV 2011, DOI: 10.1002/ijc.26427

  18. Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists

    Internal Medicine Journal

    Volume 45, Issue 8, August 2015, Pages: 834–842, L. Chim, G. Salkeld, M. R. Stockler and L. Mileshkin

    Article first published online : 28 JUL 2015, DOI: 10.1111/imj.12802

  19. You have free access to this content
    Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

    Cancer

    Volume 119, Issue 2, 15 January 2013, Pages: 339–347, Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad and Virginia E. Paton

    Article first published online : 18 JUL 2012, DOI: 10.1002/cncr.27745

  20. You have free access to this content
    Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer

    Cancer

    Volume 116, Issue 10, 15 May 2010, Pages: 2401–2408, William N. William Jr, Merrill S. Kies, Frank V. Fossella, Diane D. Liu, Gregory Gladish, Warner H. Tse, J. Jack Lee, Waun K. Hong, Scott M. Lippman and Edward S. Kim

    Article first published online : 11 MAR 2010, DOI: 10.1002/cncr.24996